[HTML][HTML] SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
E Hoffmann, GG Nomikos, I Kaul, S Raines… - Clinical …, 2020 - Springer
Background SAGE-217, a novel γ-aminobutyric acid A (GABA A) receptor positive allosteric
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
E Hoffmann, GG Nomikos, I Kaul… - Clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Background SAGE-217, a novel γ-aminobutyric acid A (GABA A) receptor positive allosteric
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
[HTML][HTML] SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
E Hoffmann, GG Nomikos, I Kaul, S Raines… - Clinical …, 2020 - ncbi.nlm.nih.gov
Background SAGE-217, a novel γ-aminobutyric acid A (GABA A) receptor positive allosteric
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
SAGE‑217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose‑Finding Studies
E Hoffmann, GG Nomikos, I Kaul… - Clinical …, 2020 - search.proquest.com
Background SAGE-217, a novel γ-aminobutyric acid A (GABAA) receptor positive allosteric
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies.
E Hoffmann, GG Nomikos, I Kaul, S Raines… - Clinical …, 2020 - europepmc.org
Background SAGE-217, a novel γ-aminobutyric acid A (GABA A) receptor positive allosteric
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …